Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study
Chenjie Gu, Jingying Zhou, Le Kang, Ming Fang · 2026
Read Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study by Chenjie Gu, Jingying Zhou, Le Kang, Ming Fang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601288.txt.
Description
Chenjie Gu and three co-authors wrote this 2026 study comparing two steroid treatments for a kidney disease called IgA nephropathy. Standard body-wide steroids cut protein leaking into urine but bring heavy side effects. Nefecon, a targeted-release form that acts in the gut, aims for the same gain with less harm. The team reviewed real-world records of 108 patients, half on each drug.
After a year, the targeted drug won on the main measures. Protein in urine fell by half on average, against a third with standard steroids. Remission came to three-fifths of the targeted group, more than double the other arm. Kidney function also trended better. Serious side effects struck eight patients on standard steroids and only one on the targeted drug. The authors still ask for bigger, forward-looking trials to confirm the gap.
Catalog record
| CREATOR | Chenjie Gu, Jingying Zhou, Le Kang, Ming Fang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |